Humacyte, Inc.
HUMA · NASDAQ
Market closed$0.664700$0.005100 (+0.77%)After hours $0.676000 · +1.70%
Key statistics
Previous close$0.659600
Open$0.648800
Day high$0.669800
Day low$0.640000
52-week high$2.84
52-week low$0.547000
Market cap111.67M
Volume4.00M
Average volume10.50M
P/E ratio-1.11
Forward P/E—
EPS-0.60
Dividend yield0.00%
Market context
Why it moved
Humacyte (HUMA) edged modestly higher, supported by analyst coverage maintaining a "Moderate Buy" rating and renewed investor interest following the company's better-than-expected earnings loss per share in its latest report, even as the stock remains near its one-year low.
What is happening
Recent company-specific developments and publisher coverage.
The Globe and Mail · July 14, 2026Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis AccessStock Titan · July 14, 2026Two Kidney Specialists Join Humacyte Ahead of Planned Dialysis AccessInvesting.com · July 14, 2026Humacyte appoints two nephrologists as commercial advisorsStock Titan · July 13, 2026Fresenius to sell 5M Humacyte (HUMA) shares under Rule 10b5-1 planStock Titan · June 10, 2026Biotech Humacyte plans stock sale to fund Symvess dialysis pushVascular News · May 12, 2026Todd Rasmussen joins Humacyte as chief surgical officerVascular News · February 23, 2026Humacyte’s Symvess supports high rates of limb salvage at 36 months in latest data drop Benzinga · June 17, 2026TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25 Benzinga · June 15, 2026Humacyte Reports Results From Its V012 Phase 3 Trial Of Bioengineered Blood Vessel At Society For Vascular Surgery's Vascular Annual Meeting Benzinga · June 11, 2026Why Is Humacyte Stock Falling Thursday? Mt Newswire · June 10, 2026Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall Benzinga · June 10, 2026Humacyte Commences Common Stock Offering; Terms Not Disclosed Benzinga · June 10, 2026Humacyte Announces Positive Interim Results From Phase Study Of Acellular Tissue Engineered Vessel In Female Patients For Dialysis Access, To Present Results June 11 Benzinga · June 8, 2026BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target Benzinga · June 1, 2026Benchmark Maintains Speculative Buy on Humacyte, Raises Price Target to $2